Next Article in Journal
Roles of Nitric Oxide and Asymmetric Dimethylarginine in Pregnancy and Fetal Programming
Next Article in Special Issue
Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Previous Article in Journal
Chronic Supplementation of Paeonol Combined with Danshensu for the Improvement of Vascular Reactivity in the Cerebral Basilar Artery of Diabetic Rats
Previous Article in Special Issue
Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
Open AccessReview

Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?

Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, Building 1242, DK-8000, Aarhus C, Denmark
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2012, 13(11), 14579-14605; https://doi.org/10.3390/ijms131114579
Received: 29 September 2012 / Revised: 23 October 2012 / Accepted: 5 November 2012 / Published: 9 November 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
Multiple sclerosis is a disease of the central nervous system, resulting in the demyelination of neurons, causing mild to severe symptoms. Several anti-inflammatory treatments now play a significant role in ameliorating the disease. Glatiramer acetate (GA) is a formulation of random polypeptide copolymers for the treatment of relapsing-remitting MS by limiting the frequency of attacks. While evidence suggests the influence of GA on inflammatory responses, the targeted molecular mechanisms remain poorly understood. Here, we review the multiple pharmacological modes-of-actions of glatiramer acetate in treatment of multiple sclerosis. We discuss in particular a newly discovered interaction between the leukocyte-expressed integrin αMβ2 (also called Mac-1, complement receptor 3, or CD11b/CD18) and perspectives on the GA co-polymers as an influence on the function of the innate immune system. View Full-Text
Keywords: glatiramer acetate; copaxone; biosimilar; integrin; immunotherapy glatiramer acetate; copaxone; biosimilar; integrin; immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Jalilian, B.; Einarsson, H.B.; Vorup-Jensen, T. Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System? Int. J. Mol. Sci. 2012, 13, 14579-14605.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop